Studies of Efficacy of tenofoviralafenamide in the treatment of chronic hepatitis B infection
- VernacularTitle:Гепатитийн в вирусийн халдварыг тенофовир алафенамид эмээр эмчилсэн үр дүнг судлах нь
- Author:
Tuvshinbayar N
1
;
Amaraa R
1
;
Burmaajav B
2
;
Gegeebadrakh B
1
;
Dulguun B
1
Author Information
1. Second General Hospital
2. Ach Medical University
- Publication Type:Review
- Keywords:
Chronic hepatitis B infection;
HBV-DNA;
HBsAg;
HBeAg;
tenofoviralafenamidfumarate(TAF);
tenofovirdisoproxil fumarate(TDF)
- From:Mongolian Medical Sciences
2019;188(2):47-52
- CountryMongolia
- Language:Mongolian
-
Abstract:
Worldwide, an estimated two billion people have evidence of HBV infection, and approximately 240 million have CHB. In April 2017, EASL added a drug newly approved for treatment of CHB, tenofoviralafenamide (TAF) to their list of recommended first-line therapies. Treatment with these therapies can achieve sustained suppression of HBV DNA replication, decreases in inflammation, and histological activity that decrease the risk of cirrhosis and hepatocellular carcinoma in both cirrhotic and noncirrhotic patients and, ultimately, of CHB-associated mortality [1, 2]. However, recent advances in understanding the HBV life cycle have enabled multiple, novel therapeutic targets to be identified and new therapies of direct-acting antiviral (DAAs) and host-targeting agents (HTAs) are indevelopment.
In most clinical trials, TAF was non-inferior to TDF in achieving HBV DNA levels below 29 IU/ml.No
amino-acid substitutions associated with viral breakthrough were detected by deep sequencing, and no resistance to TAF.With clear evidence from major studies showing that TAF is safe, tolerable, and non-inferior to TDF, its recommendation as a first-line therapy is appropriate.
Long-term safety is an important consideration in the therapeutic management of patients with CHB
because treatment is often life-long.
The efficacy of TAF in patients with resistance mutations associated with older nucleos(t)ide analogues is unclear. Although no evidence of TAF or TDF resistance was detected in the phase III studies through 96 weeks of treatment, very small numbers of patients had baseline mutations indicating resistance to lamivudine, adefovir or entecavir and efficacy data specifically for this group is not available.
- Full text:2019-188(2);47-52.pdf
